Toggle Offcanvas
...
 
Dupilumab Tenders

Dupilumab Tenders

View Dupilumab tenders, RFPs and contracts. Bid on readily available Dupilumab tenders with the best and most comprehensive tendering platform, since 2002.
Dupilumab is a biologic medication used to treat eczema, asthma, and other inflammatory conditions. It helps control the immune system’s overreaction, reducing symptoms like skin irritation and breathing difficulties.

Bidding for Dupilumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Dupilumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Dupilumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Dupilumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

14 Live Notices for Dupilumab Tenders

Showing 1 to 14

Biological Treatment Of Antiviral And Ophthalmology Ex 2025
country Czech Republic
posting date29 Sep 2025
deadline22 Oct 2025
0000812/2025 Framework Agreement With A Single Company By Which The Conditions For The Acquisition Of Supply Medicines For The Members Of The Provincial Purchasing Central Of Almería Of Successive Tract And Unit Price Are Set, Under Article 16.3.A) Of The Lcsp, By Open Procedure, Subject To Harmonized Regulation And Electronic Presentation Of Offers
country Spain
posting date26 Sep 2025
deadline10 Oct 2025
Object: Electronic Auction - Price Registration For The Acquisition Of High Cost Drugs For Hige Cost Pharmacy
country Brazil
posting date26 Sep 2025
deadline10 Oct 2025
0000634/2025 Supply Of Exclusive Medicines Xiii (Related In Annex I Of The Ppt) For The Health Centers That Make Up The Provincial Purchas
country Spain
posting date24 Sep 2025
deadline09 Oct 2025
Object: Electronic Auction - Acquisition Of Medicines For Judicial Demand Meeting
country Brazil
posting date24 Sep 2025
deadline08 Oct 2025
Successive Delivery Of Drugs Covered By Drugs For Moderate Treatment And Severe Form Of Crushing Psoriasis And A Severe Form Of Atopic Dermatitis Ad.
country Poland
posting date19 Sep 2025
deadline21 Oct 2025
Acquisition Of The Medication Dupilumab Liquido Parenteral S.I. 150 Mg/Ml Cj X Amps
country Ecuador
posting date19 Sep 2025
deadline03 Oct 2025
Psamsp 76/2025_Svilla_0000724/2025_Suminist Of Successive Tract And Unit Price Of Exclusive Medicines, For All Centers Assked To The Provincial Purchase Center Of Sevilla (Cpc-Se), Through A Negotiated Procedure Without Advertising With The Company Sanofi Aventis, S.A., Ordinary Processing And Electronic Presentation Of Offers. (6.Clut7Pa)
country Spain
posting date15 Sep 2025
deadline15 Oct 2025
Biological Treatment Of Antiviral And Ophthalmology Ex 2025
country Czech Republic
posting date12 Sep 2025
deadline16 Oct 2025
0000812/2025 Framework Agreement With A Single Company By Which The Conditions For The Acquisition Of Supply Medicines For The Members Of The Provincial Purchasing Central Of Almería Of Successive Tract And Unit Price Are Set, Under Article 16.3.A) Of The Lcsp, By Open Procedure, Subject To Harmonized Regulation And Electronic Presentation Of Offers
country Spain
posting date11 Sep 2025
deadline10 Oct 2025
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Dupilumab, Atc D11Ah05 For The Period 01.05.2025 - 30.04.2027
country Germany
posting date18 Mar 2025
deadline05 Mar 2027
Medicines With The Active Ingredient Dupilumab (Atc: D11Ah05)
country Germany
posting date23 Apr 2024
deadline31 Mar 2026
Medicines With The Active Ingredient Dupilumab (Atc: D11Ah05)
country Germany
posting date20 Apr 2024
deadline31 Mar 2026
Completion Of A Non-Exclusive Discount Contract According To Section 130C Paragraph 1 Sgb V For Dupilumab, Atc Code: D11Ah05 For The Period From December 1St, 2023 To November 30Th, 2025
country Germany
posting date03 Nov 2023
deadline03 Oct 2025

Share Share this page